DERMAPHARM HOLDING SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.3 EUR | +0.81% |
|
-1.88% | -26.07% |
| Apr. 04 | DERMAPHARM : Berenberg keeps its Buy rating | ZD |
| Mar. 28 | Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,140 | 3,067 | 4,808 | 2,020 | 2,280 | 1,685 | - | - |
| Enterprise Value (EV) 1 | 2,606 | 3,554 | 5,206 | 2,388 | 3,216 | 2,497 | 2,384 | 2,304 |
| P/E ratio | 27.8 x | 35.8 x | 23 x | 15.1 x | 36.5 x | 15 x | 13 x | 12.1 x |
| Yield | 2.01% | 1.54% | 2.43% | 2.8% | 2.08% | 3.36% | 3.84% | 4.31% |
| Capitalization / Revenue | 3.05 x | 3.86 x | 5.1 x | 1.97 x | 2.01 x | 1.45 x | 1.38 x | 1.32 x |
| EV / Revenue | 3.72 x | 4.48 x | 5.52 x | 2.33 x | 2.83 x | 2.14 x | 1.95 x | 1.81 x |
| EV / EBITDA | 14.7 x | 17.7 x | 14.8 x | 6.64 x | 10.4 x | 8.18 x | 7.31 x | 6.7 x |
| EV / FCF | -9.25 x | 39.4 x | 27.5 x | 9.57 x | 18.1 x | 15.6 x | 13.3 x | 12.2 x |
| FCF Yield | -10.8% | 2.54% | 3.63% | 10.4% | 5.53% | 6.42% | 7.5% | 8.2% |
| Price to Book | 7.68 x | 9.52 x | 9.67 x | 3.8 x | 4.23 x | 2.74 x | 2.45 x | 2.27 x |
| Nbr of stocks (in thousands) | 53,840 | 53,840 | 53,840 | 53,840 | 53,840 | 53,840 | - | - |
| Reference price 2 | 39.75 | 56.96 | 89.30 | 37.52 | 42.34 | 31.30 | 31.30 | 31.30 |
| Announcement Date | 4/8/20 | 4/12/21 | 4/12/22 | 3/28/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 700.9 | 793.8 | 942.9 | 1,025 | 1,135 | 1,166 | 1,220 | 1,275 |
| EBITDA 1 | 177.6 | 200.7 | 351.1 | 359.8 | 310.2 | 305.2 | 326 | 343.7 |
| EBIT 1 | 119.5 | 136.9 | 298.5 | 243.7 | 182.9 | 210.8 | 232 | 250.4 |
| Operating Margin | 17.05% | 17.24% | 31.65% | 23.78% | 16.11% | 18.08% | 19.02% | 19.64% |
| Earnings before Tax (EBT) 1 | 110.1 | 125.3 | 293 | 216.3 | 106 | 163.8 | 188.3 | 198.5 |
| Net income 1 | 77.2 | 85.83 | 209.6 | 134.2 | 62.37 | 112.1 | 129.6 | 139.3 |
| Net margin | 11.01% | 10.81% | 22.23% | 13.1% | 5.49% | 9.62% | 10.62% | 10.93% |
| EPS 2 | 1.430 | 1.590 | 3.890 | 2.490 | 1.160 | 2.083 | 2.408 | 2.587 |
| Free Cash Flow 1 | -281.5 | 90.3 | 189.2 | 249.5 | 177.9 | 160.4 | 178.8 | 188.9 |
| FCF margin | -40.17% | 11.38% | 20.06% | 24.35% | 15.67% | 13.76% | 14.65% | 14.82% |
| FCF Conversion (EBITDA) | - | 44.99% | 53.88% | 69.35% | 57.34% | 52.54% | 54.85% | 54.96% |
| FCF Conversion (Net income) | - | 105.22% | 90.26% | 185.88% | 285.21% | 143.01% | 137.92% | 135.56% |
| Dividend per Share 2 | 0.8000 | 0.8800 | 2.170 | 1.050 | 0.8800 | 1.052 | 1.202 | 1.350 |
| Announcement Date | 4/8/20 | 4/12/21 | 4/12/22 | 3/28/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 242.4 | 231.6 | - | 263.1 | 290.5 | 319.1 | 263 | 582.1 | - | 268.8 |
| EBITDA 1 | 90.8 | 75.1 | 73.6 | 83.2 | 120.4 | 105.8 | 62.2 | 168 | - | 66.4 |
| EBIT | 85.06 | 58.09 | 32.94 | 75.84 | - | - | - | - | - | - |
| Operating Margin | 35.08% | 25.08% | - | 28.82% | - | - | - | - | - | - |
| Earnings before Tax (EBT) | 81.84 | - | - | - | - | - | - | - | - | - |
| Net income | 61.81 | 37.14 | 14.52 | 52.46 | - | 49.1 | - | - | 24.84 | - |
| Net margin | 25.49% | 16.03% | - | 19.94% | - | 15.39% | - | - | - | - |
| EPS | 1.150 | 0.6900 | 0.2700 | - | - | - | - | - | 0.4600 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/16/21 | 5/18/22 | 9/7/22 | 11/16/22 | 3/28/23 | 5/15/23 | 8/29/23 | 8/29/23 | 11/16/23 | 3/28/24 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 465 | 487 | 398 | 368 | 937 | 812 | 699 | 619 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.621 x | 2.426 x | 1.134 x | 1.022 x | 3.019 x | 2.659 x | 2.143 x | 1.801 x |
| Free Cash Flow 1 | -282 | 90.3 | 189 | 250 | 178 | 160 | 179 | 189 |
| ROE (net income / shareholders' equity) | 29.1% | 26.5% | 35.5% | 26.1% | 11.6% | 18.2% | 19% | 18.1% |
| ROA (Net income/ Total Assets) | - | - | 14.9% | - | - | - | - | - |
| Assets 1 | - | - | 1,407 | - | - | - | - | - |
| Book Value Per Share 2 | 5.180 | 5.980 | 9.240 | 9.870 | 10.00 | 11.40 | 12.80 | 13.80 |
| Cash Flow per Share 2 | 1.870 | 2.440 | 4.650 | 5.360 | 4.080 | 3.360 | 3.090 | 3.060 |
| Capex 1 | 46.4 | 40.8 | 61.2 | 39 | 41.5 | 45.5 | 50.1 | 51.7 |
| Capex / Sales | 6.63% | 5.14% | 6.49% | 3.81% | 3.66% | 3.91% | 4.1% | 4.05% |
| Announcement Date | 4/8/20 | 4/12/21 | 4/12/22 | 3/28/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31.3
EUR
Average target price
56.9
EUR
Spread / Average Target
+81.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.07% | 1.8B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DMP Stock
- Financials Dermapharm Holding SE
